Cargando…
Biosimilars: How Can Payers Get Long-Term Savings?
The term ‘biosimilar’ refers to an alternative similar version of an off-patent innovative originator biotechnology product (the ‘reference product’). Several biosimilars have been approved in Europe, and a number of top-selling biological medicines have lost, or will lose, patent protection over th...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4863918/ https://www.ncbi.nlm.nih.gov/pubmed/26792791 http://dx.doi.org/10.1007/s40273-015-0380-x |